{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:46:35Z","timestamp":1794465995731,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Jilin Province Science and Technology Development Plan","award":["YDZJ202501ZYTS253"],"award-info":[{"award-number":["YDZJ202501ZYTS253"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01877-4","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T08:03:35Z","timestamp":1754467415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Yanying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanchi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"10191","key":"1877_CR1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Sayer AA, Sarcopenia. Lancet. 2019;393(10191):2636\u201346.","journal-title":"Lancet"},{"key":"1877_CR2","first-page":"21","volume":"20","author":"S Safiri","year":"2023","unstructured":"Safiri S, Asghari KM, Sullman MJ. The global burden of diseases and injuries among older adults. Science. 2023;20:21.","journal-title":"Science"},{"issue":"1","key":"1877_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13098-023-01057-2","volume":"15","author":"M Zarezadeh","year":"2023","unstructured":"Zarezadeh M, Musazadeh V, Foroumandi E, Keramati M, Ostadrahimi A, Mekary RA. The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes or with polycystic ovary syndrome: an umbrella meta-analysis on interventional meta-analyses. DIABETOL METAB SYNDR. 2023;15(1):127.","journal-title":"DIABETOL METAB SYNDR"},{"key":"1877_CR4","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. DIABETES RES CLIN PR. 2022;183:109119.","journal-title":"DIABETES RES CLIN PR"},{"issue":"1","key":"1877_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/nu13010183","volume":"13","author":"A Izzo","year":"2021","unstructured":"Izzo A, Massimino E, Riccardi G, Della Pepa G. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. NUTRIENTS. 2021;13(1):183.","journal-title":"NUTRIENTS"},{"key":"1877_CR6","doi-asserted-by":"crossref","unstructured":"Chen H, Huang X, Dong M, Wen S, Zhou L, Yuan X. The association between sarcopenia and diabetes: from pathophysiology mechanism to therapeutic strategy. Diabetes Metabolic Syndrome Obes 2023: 1541\u201354.","DOI":"10.2147\/DMSO.S410834"},{"issue":"7","key":"1877_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2337\/dc09-2310","volume":"33","author":"TN Kim","year":"2010","unstructured":"Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean sarcopenic obesity study (KSOS). Diabetes Care. 2010;33(7):1497\u20139.","journal-title":"Diabetes Care"},{"key":"1877_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1590\/1809-9823.2015.14139","volume":"18","author":"JBM Diz","year":"2015","unstructured":"Diz JBM, Queiroz BZD, Tavares LB, Pereira LSM. Prevalence of sarcopenia among the elderly: findings from broad cross-sectional studies in a range of countries. Revista Brasileira De Geriatria E Gerontologia. 2015;18:665\u201378.","journal-title":"Revista Brasileira De Geriatria E Gerontologia"},{"issue":"8","key":"1877_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/nu14081537","volume":"14","author":"N Almohaisen","year":"2022","unstructured":"Almohaisen N, Gittins M, Todd C, et al. Prevalence of undernutrition, frailty and sarcopenia in community-dwelling people aged 50 years and above: systematic review and meta-analysis. Nutrients. 2022;14(8):1537.","journal-title":"NUTRIENTS"},{"issue":"6","key":"1877_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00198-017-3980-9","volume":"28","author":"C Beaudart","year":"2017","unstructured":"Beaudart C, Dawson A, Shaw SC, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos INT. 2017;28(6):1817\u201333.","journal-title":"Osteoporos INT"},{"issue":"8","key":"1877_CR11","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/cells10081958","volume":"10","author":"E Massimino","year":"2021","unstructured":"Massimino E, Izzo A, Riccardi G, Della Pepa G. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. CELLS-BASEL. 2021;10(8):1958.","journal-title":"CELLS-BASEL"},{"issue":"3","key":"1877_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/1573399816666200705210006","volume":"17","author":"S Ida","year":"2021","unstructured":"Ida S, Kaneko R, Imataka K, et al. Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Curr Diabetes Rev. 2021;17(3):293\u2013303.","journal-title":"CURR DIABETES REV"},{"issue":"6","key":"1877_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.5246\/jcps.2024.06.036","volume":"33","author":"L Tan","year":"2024","unstructured":"Tan L, Fu Y. Exploring the impact of anti-diabetic medications on sarcopenia: a comprehensive review. J Chin Pharm Sci. 2024;33(6):481.","journal-title":"J Chin Pharm Sci"},{"key":"1877_CR14","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.curtheres.2025.100788","volume":"102","author":"V Musazadeh","year":"2025","unstructured":"Musazadeh V, Hamidi N, Noormohammadi M, Shidfar F. The effect of berberis (Vulgaris and Integerrima) on cardiovascular risk factors in patients with type 2 diabetes mellitus: A systematic review, Meta-Analysis, and GRADE assessment. Curr Therapeutic Res Clin Experimental. 2025;102:100788.","journal-title":"Curr Therapeutic Res Clin Experimental"},{"key":"1877_CR15","first-page":"712911025","volume":"14","author":"D Ja Arah","year":"2021","unstructured":"Ja Arah D, Al Zoubi MS, Abdelhady G, Rabi F, Tambuwala MM. Role of glucagon-like peptide-1 (GLP-1) receptor agonists in hypoglycemia. Clin Med Insights: Endocrinol Diabetes. 2021;14:712911025.","journal-title":"Clin Med Insights: Endocrinol Diabetes"},{"key":"1877_CR16","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res Ed. 2021;372:n71.","journal-title":"BMJ (Clinical Res Ed"},{"key":"1877_CR17","unstructured":"Higgins J, Thomas J, Chandler J, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024.; 2024."},{"issue":"3","key":"1877_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jrsm.1232","volume":"8","author":"BU Burda","year":"2017","unstructured":"Burda BU, O\u2019Connor EA, Webber EM, Redmond N, Perdue LA. Estimating data from figures with a Web-based program: considerations for a systematic review. RES SYNTH METHODS. 2017;8(3):258\u201362.","journal-title":"RES SYNTH METHODS"},{"key":"1877_CR19","first-page":"1","volume":"3CSCW","author":"N McDonald","year":"2019","unstructured":"McDonald N, Schoenebeck S, Forte A. Reliability and inter-rater reliability in qualitative research: norms and guidelines for CSCW and HCI practice. Proc ACM Hum Comput Interact. 2019;3CSCW:1\u201323.","journal-title":"Proc ACM Hum Comput Interact"},{"key":"1877_CR20","first-page":"l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res Ed. 2019;366:l4898.","journal-title":"BMJ (Clinical Res Ed"},{"issue":"5","key":"1877_CR21","doi-asserted-by":"publisher","first-page":"103241","DOI":"10.1016\/j.dsx.2025.103241","volume":"19","author":"V Musazadeh","year":"2025","unstructured":"Musazadeh V, Nezamoleslami S, Faghfouri AH, Shidfar F, Aryaeian N. The effect of flaxseed supplementation on anthropometric indices, blood pressure, and lipid profile in diabetic patients: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. Diabetes Metabolic Syndrome. 2025;19(5):103241.","journal-title":"Diabetes Metabolic Syndrome"},{"key":"1877_CR22","unstructured":"Ahmad WMAW, Ghazali FMM, Yaqoob MA. Basic statistical analysis using RStudio software: Penerbit USM: 2023."},{"key":"1877_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J stat Softw. 2010;36:1\u201348.","journal-title":"J STAT SOFTW"},{"issue":"1","key":"1877_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. Bmc Med Res Methodol. 2014;14(1):25.","journal-title":"BMC MED RES METHODOL"},{"issue":"1","key":"1877_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/jep.13159","volume":"26","author":"L Lin","year":"2020","unstructured":"Lin L. Comparison of four heterogeneity measures for meta-analysis. J EVAL CLIN PRACT. 2020;26(1):376\u201384.","journal-title":"J EVAL CLIN PRACT"},{"issue":"10","key":"1877_CR26","first-page":"ED000142","volume":"2019","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;2019(10):ED000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"1877_CR27","unstructured":"Deeks JJ, Higgins JP, Altman DG et al. Chapter 10: chap. 10: analysing data and undertaking meta-analyses. Cochrane Handb Syst Reviews Interventions [Internet] 2024; 6."},{"issue":"6","key":"1877_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.295.6.676","volume":"295","author":"JL Peters","year":"2006","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. Jama-J Am Med Assoc. 2006;295(6):676\u201380.","journal-title":"JAMA-J AM MED ASSOC"},{"issue":"11","key":"1877_CR64","first-page":"982","volume":"60","author":"Y Dongni","year":"2021","unstructured":"Dongni Y, Lijuan W, Bo C, Miao L, Qi. P, Lixin G. The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus. Chin J Intern Med. 2021;60(11):982\u20136.","journal-title":"Chin J Intern Med"},{"issue":"03","key":"1877_CR65","first-page":"144","volume":"9","author":"Z Hongmin","year":"2019","unstructured":"Hongmin Z, Jinlin W, Xingyu Z, Mei Y. The effect of liraglutide combined with Metformin on the function of islet \u03b2 cells and visceral fat level in patients with type, type 2 diabetes and obesity. Chin J Cells Stem Cells (Electronic Edition). 2019;9(03):144\u20138.","journal-title":"Chin J Cells Stem Cells (Electronic Edition)"},{"issue":"11","key":"1877_CR66","first-page":"9","volume":"15","author":"X Xuejuan","year":"2018","unstructured":"Xuejuan X, Xiaojun L, Jinsong C. Comparison of Metformin combined with insulin Detemir or liraglutide to treat type 2 diabetes mellitus with sarcopenia. Drug Evaluation. 2018;15(11):9\u201311.","journal-title":"Drug Evaluation"},{"issue":"11","key":"1877_CR67","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1055\/a-2145-1004","volume":"131","author":"L Liu","year":"2023","unstructured":"Liu L, Wang R, Gao J, et al. Insulin glargine is more suitable than exenatide in preventing muscle loss in Non-Obese type 2 diabetic patients with NAFLD. Experimental and clinical endocrinology & diabetes: official journal. German Soc Endocrinol [and] German Diabetes Association. 2023;131(11):583\u20138.","journal-title":"German Soc Endocrinol [and] German Diabetes Association"},{"issue":"3","key":"1877_CR68","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","volume":"64","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, Nakano Y, Fukuda T, et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J. 2017;64(3):269\u201381.","journal-title":"ENDOCR J"},{"issue":"18","key":"1877_CR29","first-page":"6813","volume":"26","author":"L Keskin","year":"2022","unstructured":"Keskin L, Yaprak B. Comparison of the effect of liraglutide and Metformin therapy on the disease regulation and weight loss in obese patients with type 2 diabetes mellitus. Eur Rev Med Pharmaco. 2022;26(18):6813.","journal-title":"EUR REV MED PHARMACO"},{"issue":"3","key":"1877_CR69","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s13340-024-00717-6","volume":"15","author":"Y Kondo","year":"2024","unstructured":"Kondo Y, Satoh S, Terauchi Y. Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study. DIABETOL INT. 2024;15(3):474\u201382.","journal-title":"DIABETOL INT"},{"key":"1877_CR70","unstructured":"Jiajun B, Ting G. J Yilan. Effects of liraglutide combined with Metformin on blood glucose and skeletal muscle mass index in diabetic patients with sarcopenia. Chin Sci Technol J Database (Full-text Version) Med Health 2025;(5): 125\u20138."},{"issue":"8","key":"1877_CR71","first-page":"1","volume":"28","author":"Z Xueding","year":"2025","unstructured":"Xueding Z, Xiaoya W. Effects of smeglutide on skeletal muscle and visceral fat in obese patients with type 2 diabetes mellitus. Diabetes New World. 2025;28(8):1\u20134.","journal-title":"Diabetes New World"},{"issue":"6","key":"1877_CR30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/jdi.13436","volume":"12","author":"H Mori","year":"2021","unstructured":"Mori H, Kuroda A, Yoshida S, et al. High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: findings from the impact of diabetes mellitus on dynapenia study. J Diabetes Invest. 2021;12(6):1050\u20139.","journal-title":"J DIABETES INVEST"},{"key":"1877_CR31","doi-asserted-by":"publisher","first-page":"656909","DOI":"10.3389\/fphys.2021.656909","volume":"12","author":"J Paquin","year":"2021","unstructured":"Paquin J, Lagac\u00e9 J, Brochu M, Dionne IJ. Exercising for insulin sensitivity\u2013is there a mechanistic relationship with quantitative changes in skeletal muscle mass? Front Physiol. 2021;12:656909.","journal-title":"FRONT PHYSIOL"},{"issue":"9","key":"1877_CR32","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1210\/en.2006-0251","volume":"147","author":"X Wang","year":"2006","unstructured":"Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147(9):4160\u20138.","journal-title":"Endocrinology"},{"issue":"6","key":"1877_CR33","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","volume":"478","author":"K Ramasubbu","year":"2023","unstructured":"Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced ages on diabetes mellitus and neurodegenerative diseases: a perspective review. MOL CELL BIOCHEM. 2023;478(6):1307\u201324.","journal-title":"MOL CELL BIOCHEM"},{"issue":"1","key":"1877_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1172\/JCI88880","volume":"127","author":"H Wu","year":"2017","unstructured":"Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Investig. 2017;127(1):43\u201354.","journal-title":"J Clin Investig"},{"issue":"8","key":"1877_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jamda.2013.02.006","volume":"14","author":"M Leenders","year":"2013","unstructured":"Leenders M, Verdijk LB, van der Hoeven L, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir AssoC. 2013;14(8):585\u201392.","journal-title":"J AM MED DIR ASSOC"},{"issue":"11","key":"1877_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/bioengineering8110168","volume":"8","author":"LC Olson","year":"2021","unstructured":"Olson LC, Redden JT, Schwartz Z, Cohen DJ, McClure MJ. Advanced glycation end-products in skeletal muscle aging. Bioengineering. 2021;8(11):168.","journal-title":"Bioengineering"},{"issue":"13","key":"1877_CR37","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.2174\/0929867326666181129095309","volume":"27","author":"B Sharma","year":"2020","unstructured":"Sharma B, Dabur R. Role of pro-inflammatory cytokines in regulation of skeletal muscle metabolism: a systematic review. Curr Med Chem. 2020;27(13):2161\u201388.","journal-title":"CURR MED CHEM"},{"key":"1877_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jad.2023.12.002","volume":"347","author":"H Zheng","year":"2024","unstructured":"Zheng H, Hua D, Jin X, Zheng X. The association of depressive sarcopenia and cognitive decline among the elderly: evidence from the survey of health and retirement in Europe. J Affect Disorders. 2024;347:492\u20139.","journal-title":"J AFFECT DISORDERS"},{"issue":"1","key":"1877_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12877-022-02826-w","volume":"22","author":"C Lin","year":"2022","unstructured":"Lin C, Ou H, Hsu H, et al. Beyond sarcopenia: older adults with type II diabetes mellitus tend to experience an elevated risk of poor dynamic balance\u2014a case\u2013control study. BMC Geriatr. 2022;22(1):138.","journal-title":"BMC GERIATR"},{"key":"1877_CR40","doi-asserted-by":"crossref","unstructured":"Committee ADAP, Committee ADAP. 13. Older adults: standards of medical care in diabetes\u20142022. Diabetes Care 2022; 45(Supplement_1): S195-207.","DOI":"10.2337\/dc22-S013"},{"issue":"1","key":"1877_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-023-03065-z","volume":"25","author":"DR Moellering","year":"2023","unstructured":"Moellering DR, Smith-Johnston K, Kelley C, et al. Association between skeletal muscle mitochondrial dysfunction and insulin resistance in patients with rheumatoid arthritis: a case\u2013control study. Arthritis Res Ther. 2023;25(1):85.","journal-title":"ARTHRITIS RES THER"},{"issue":"4","key":"1877_CR42","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cmet.2021.03.020","volume":"33","author":"L Sylow","year":"2021","unstructured":"Sylow L, Tokarz VL, Richter EA, Klip A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 2021;33(4):758\u201380.","journal-title":"CELL METAB"},{"key":"1877_CR43","doi-asserted-by":"publisher","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","volume":"12","author":"X Zhao","year":"2021","unstructured":"Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2021;12:721135.","journal-title":"FRONT ENDOCRINOL"},{"issue":"3","key":"1877_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pharmthera.2008.05.008","volume":"119","author":"DS Hutchinson","year":"2008","unstructured":"Hutchinson DS, Summers RJ, Bengtsson T. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Therapeut. 2008;119(3):291\u2013310.","journal-title":"PHARMACOL THERAPEUT"},{"issue":"16","key":"1877_CR45","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.3390\/jcm13164674","volume":"13","author":"R Le","year":"2024","unstructured":"Le R, Nguyen MT, Allahwala MA, et al. Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs. J Clin Med. 2024;13(16):4674.","journal-title":"J CLIN MED"},{"key":"1877_CR46","doi-asserted-by":"crossref","unstructured":"Ren Q, Chen S, Chen X et al. An effective glucagon-like peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism. Drug Des Devel Ther 2022: 3723\u201335.","DOI":"10.2147\/DDDT.S381546"},{"issue":"7","key":"1877_CR47","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/1753-0407.13045","volume":"12","author":"KM Love","year":"2020","unstructured":"Love KM, Liu J, Regensteiner JG, Reusch JE, Liu Z. GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J DIABETES. 2020;12(7):488\u201398.","journal-title":"J DIABETES"},{"issue":"8","key":"1877_CR48","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.2337\/db13-1597","volume":"63","author":"W Chai","year":"2014","unstructured":"Chai W, Zhang X, Barrett EJ, Liu Z. Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin\u2019s metabolic action in the presence of insulin resistance. Diabetes. 2014;63(8):2788\u201399.","journal-title":"Diabetes"},{"issue":"5","key":"1877_CR49","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/jcsm.13524","volume":"15","author":"HH Huang","year":"2024","unstructured":"Huang HH, Wang YJ, Jiang HY, et al. Sarcopenia-related changes in serum GLP\u20101 level affect myogenic differentiation. J Cachexia Sarcopenia Muscle. 2024;15(5):1708\u201321.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"1877_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/medicines9090047","volume":"9","author":"Y Ozeki","year":"2022","unstructured":"Ozeki Y, Masaki T, Kamata A, et al. The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study. Medicines. 2022;9(9):47.","journal-title":"Medicines"},{"key":"1877_CR51","doi-asserted-by":"publisher","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113.","journal-title":"METABOLISM"},{"key":"1877_CR52","doi-asserted-by":"crossref","unstructured":"Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation 2024; 150(16): 1288-98.","DOI":"10.1161\/CIRCULATIONAHA.124.067676"},{"issue":"8","key":"1877_CR53","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/nu17081303","volume":"17","author":"KK Gofron","year":"2025","unstructured":"Gofron KK, Wasilewski A, Ma\u0142gorzewicz S. Effects of GLP-1 analogues and agonists on the gut microbiota: A systematic review. Nutrients. 2025;17(8):1303.","journal-title":"NUTRIENTS"},{"key":"1877_CR54","doi-asserted-by":"publisher","first-page":"1566498","DOI":"10.3389\/fnut.2025.1566498","volume":"12","author":"B Johnson","year":"2025","unstructured":"Johnson B, Milstead M, Thomas O, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: A cross-sectional study. Front nutr. 2025;12:1566498.","journal-title":"FRONT NUTR"},{"key":"1877_CR55","doi-asserted-by":"publisher","first-page":"881121","DOI":"10.3389\/fnut.2022.881121","volume":"9","author":"C Chalermsri","year":"2022","unstructured":"Chalermsri C, Aekplakorn W, Srinonprasert V. Body mass index combined with possible sarcopenia status is better than BMI or possible sarcopenia status alone for predicting all-cause mortality among Asian community-dwelling older adults. Front Nutr. 2022;9:881121.","journal-title":"FRONT NUTR"},{"issue":"4","key":"1877_CR56","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.clnu.2020.10.021","volume":"40","author":"H Xu","year":"2021","unstructured":"Xu H, Liu J, Zhang X, et al. Estimation of skeletal muscle mass by bioimpedance and differences among skeletal muscle mass indices for assessing sarcopenia. CLIN NUTR. 2021;40(4):2308\u201318.","journal-title":"CLIN NUTR"},{"issue":"4","key":"1877_CR57","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1017\/S0007114508922558","volume":"100","author":"S Lazzer","year":"2008","unstructured":"Lazzer S, Bedogni G, Agosti F, De Col A, Mornati D, Sartorio A. Comparison of dual-energy X-ray absorptiometry, air displacement plethysmography and bioelectrical impedance analysis for the assessment of body composition in severely obese Caucasian children and adolescents. BRIT J NUTR. 2008;100(4):918\u201324.","journal-title":"BRIT J NUTR"},{"key":"1877_CR58","doi-asserted-by":"crossref","unstructured":"Wang D, Zhang G, Yu Y, Zhang Z. Imaging of sarcopenia in type 2 diabetes mellitus. Clin Interv Aging 2024: 141\u2013\u200951.","DOI":"10.2147\/CIA.S443572"},{"issue":"6","key":"1877_CR59","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00266-022-02973-w","volume":"46","author":"X Wang","year":"2022","unstructured":"Wang X, Guan J, Chen Y, Li Y, Lu F, Dong Z. Density-based high-quality fat: characterization and correlation with different body fat ratio. AEsthet Plast Surg. 2022;46(6):3003\u201312.","journal-title":"AESTHET PLAST SURG"},{"issue":"1","key":"1877_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13098-023-01056-3","volume":"15","author":"C Lin","year":"2023","unstructured":"Lin C, Li J, Wu F, et al. Comparison of lipid accumulation product and visceral adiposity index with traditional obesity indices in early-onset type 2 diabetes prediction: a cross-sectional study. Diabetol Metab Syndr. 2023;15(1):111.","journal-title":"DIABETOL METAB SYNDR"},{"issue":"3","key":"1877_CR61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000368498","volume":"40","author":"SH Kang","year":"2015","unstructured":"Kang SH, Cho KH, Park JW, Yoon KW, Do JY. Association of visceral fat area with chronic kidney disease and metabolic syndrome risk in the general population: analysis using multi-frequency bioimpedance. Kidney Blood Press Res. 2015;40(3):223\u201330.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"1877_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide\u20101 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metabolism. 2017;19(3):336\u201347.","journal-title":"Diabetes Obes Metabolism"},{"issue":"6","key":"1877_CR63","doi-asserted-by":"publisher","first-page":"e0126769","DOI":"10.1371\/journal.pone.0126769","volume":"10","author":"JE Potts","year":"2015","unstructured":"Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS ONE. 2015;10(6):e0126769.","journal-title":"PLoS ONE"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01877-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:18:58Z","timestamp":1757344738000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01877-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01877-4","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}